Dehydration News and Research RSS Feed - Dehydration News and Research

Dehydration is a condition caused by the loss of too much water from the body. Severe diarrhea or vomiting can cause dehydration.
Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). [More]
Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive topline safety and tolerability results from a Phase 1b clinical trial of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy. [More]
Readmissions after surgery associated with new postdischarge complications, shows study

Readmissions after surgery associated with new postdischarge complications, shows study

In a study that included readmission information from nearly 350 hospitals, readmissions the first 30 days after surgery were associated with new postdischarge complications related to the surgical procedure and not a worsening of any medical conditions the patient already had while hospitalized for surgery, according to a study in the February 3 issue of JAMA. [More]
Helsinn begins elsiglutide Phase IIB trial for prevention of chemotherapy-induced diarrhea

Helsinn begins elsiglutide Phase IIB trial for prevention of chemotherapy-induced diarrhea

Helsinn Healthcare S.A. and Zealand Pharma A/S jointly announce that Helsinn has started a Phase IIB clinical dose-finding trial of elsiglutide for the prevention of chemotherapy-induced diarrhea (CID). The first patients out of a planned total of 600 patients with colorectal cancer treated with chemotherapy have been dosed in the trial. [More]
Most hospital readmissions after surgery are not due to poor care coordination, finds new study

Most hospital readmissions after surgery are not due to poor care coordination, finds new study

A study from Northwestern Medicine and the American College of Surgeons published today in JAMA suggests that penalizing hospitals for patient readmissions following surgery may be ineffective, and even counterproductive, for improving the quality of hospital care in America. [More]
Study shows changes in kidney function among sugarcane workers in northwestern Nicaragua

Study shows changes in kidney function among sugarcane workers in northwestern Nicaragua

Sugarcane workers in northwestern Nicaragua experienced a decline in kidney function during the harvest, with field workers at greatest risk, suggesting that heat stress or other occupational factors may be playing a role in the high rates of chronic kidney disease in the region, a new study led by Boston University School of Public Health researchers shows. [More]
Johns Hopkins pediatricians offer guidelines on choosing between urgent care and ER

Johns Hopkins pediatricians offer guidelines on choosing between urgent care and ER

Parents have a natural tendency to fear the worst when it comes to their children and often opt for a "better safe than sorry" course of action, Canares says, but the truth is many situations don't warrant a trip to the emergency room. At the other end of the spectrum are cases that clearly require emergency attention but end up in urgent care instead — a less common scenario, Canares says. [More]
Antibiotic use by travellers may promote spread of drug-resistant 'super-bacteria'

Antibiotic use by travellers may promote spread of drug-resistant 'super-bacteria'

Treating travellers' diarrhoea with antibiotics can promote the spread of drug-resistant "super-bacteria". [More]
Taking antibiotics for diarrhea may put travelers at increased risk for contracting superbugs

Taking antibiotics for diarrhea may put travelers at increased risk for contracting superbugs

Taking antibiotics for diarrhea may put travelers visiting developing parts of the world at higher risk for contracting superbugs and spreading these daunting drug-resistant bacteria to their home countries, according to a new study published in Clinical Infectious Diseases and now available online. [More]
Almost 42% of US drinkers use alcohol-interactive prescription medications, study finds

Almost 42% of US drinkers use alcohol-interactive prescription medications, study finds

Approximately 71 percent of American adults drink alcohol. While alcohol interacts negatively with a number of commonly prescribed medications, little is known on a population level about the use of alcohol-interactive (AI) prescription medication among US drinkers. A new study has found that almost 42 percent of drinkers in the US population have used one or more alcohol-interactive prescription medications. [More]
FDA grants orphan drug status to NBI-77860 for treatment of congenital adrenal hyperplasia

FDA grants orphan drug status to NBI-77860 for treatment of congenital adrenal hyperplasia

Neurocrine Biosciences, Inc. announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, has been granted orphan drug status by the United States Food and Drug Administration (FDA) for the treatment of congenital adrenal hyperplasia (CAH) a disease that affects approximately 20,000-30,000 people in the United States. [More]
Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Arcturus Therapeutics Inc., developing the 'next wave' of RNA medicines, today announced that Joseph Payne, President and Chief Executive Officer, is scheduled to present a corporate overview, including the company's new messenger RNA (mRNA) therapeutics pipeline, at two upcoming healthcare conferences. [More]
Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy. [More]
FDA approves Novo Nordisk’s weight loss injection, Saxenda

FDA approves Novo Nordisk’s weight loss injection, Saxenda

Novo Nordisk today announced that the Food and Drug Administration (FDA) has approved the new drug application (NDA) for Saxenda® (liraglutide [rDNA origin] injection), the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management. [More]
Periods of extreme heat associated with increased hospitalization risk for older adults

Periods of extreme heat associated with increased hospitalization risk for older adults

Between 1999 and 2010, periods of extreme heat in the U.S. were associated with an increased risk of hospitalization for older adults for fluid and electrolyte disorders, kidney failure, urinary tract infections, septicemia and heat stroke, according to a study in the December 24/31 issue of JAMA. [More]
Figitumumab development discontinued for non-adenocarcinoma NSCLC

Figitumumab development discontinued for non-adenocarcinoma NSCLC

Adding the novel insulin-like growth factor 1 receptor inhibitor figitumumab to the epidermal growth factor receptor–tyrosine kinase inhibitor erlotinib does not improve survival in patients with non-adenocarcinoma non-small-cell lung carcinoma, research shows. [More]
Danish researchers working on new type of vaccine that targets disease causing bacterium

Danish researchers working on new type of vaccine that targets disease causing bacterium

When we acquire diarrhea on a vacation, it is often caused by a bacterial infection. Now a Danish research team is working on a new type of vaccine design targeting the disease causing bacterium - if it works it may very well revolutionize not only the prevention of this disease, but also offer protection against other pathogens with a heavy disease burden such as Mycobacterium tuberculosis and antibiotic-resistant Staphylococcus aureus (MRSA). [More]
UB study creates new awareness for diabetics who are at risk for dehydration

UB study creates new awareness for diabetics who are at risk for dehydration

Some drugs used to treat diabetes mimic the behavior of a hormone that a University at Buffalo psychologist has learned controls fluid intake in subjects. The finding creates new awareness for diabetics who, by the nature of their disease, are already at risk for dehydration. [More]
Tips to reduce migraine risk during holiday season

Tips to reduce migraine risk during holiday season

Certain foods and drinks can trigger migraine in many people, and those who suffer from migraines need to be especially careful to avoid these triggers as they attend holiday celebrations. With this in mind, the American Migraine Foundation and its Chair, David W. Dodick, MD, FRCP (C), FACP, want to help people with migraine avoid these potential triggers, so that they can better enjoy the season. Dr. Dodick is also Professor of Medicine at the Mayo Clinic College of Medicine (Scottsdale, AZ). [More]
Gout attacks are most common at night

Gout attacks are most common at night

Research, published today, has shown that an acute gout attack is more than twice as likely to occur during the night or early morning hours as during the day. The increased prevalence of gout attacks at night time was observed even after 24 hours with no alcohol and low purine intake. [More]